Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 139
- Registration Number
- NCT02001987
Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population
Phase 4
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: ErlotinibDrug: Chemotherapy
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02000531
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
Phase 3
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 787
- Registration Number
- NCT01998880
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 154
- Registration Number
- NCT01998919
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 330
- Registration Number
- NCT01998906
A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT01998893
A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1805
- Registration Number
- NCT01996332
A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 401
- Registration Number
- NCT01995201
A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.
Phase 1
Completed
- Conditions
- Atherosclerosis
- Interventions
- Other: NS followed by LS diet conditionOther: LS followed by NS diet conditionDrug: RO6836191Drug: Placebo
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT01995383
H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 657
- Registration Number
- NCT01991340
© Copyright 2025. All Rights Reserved by MedPath